Screener
Odyssey Therapeutics ODTX Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | $959 | — | $2,877 |
| Operating expenses: | ||||
| Research and development | 36,226 | 30,227 | 68,547 | 69,001 |
| General and administrative | 10,511 | 13,219 | 17,861 | 21,171 |
| Change in fair value of contingent consideration | 8,733 | (566) | 8,842 | (6,214) |
| Total operating expenses | 55,470 | 42,880 | 95,250 | 83,958 |
| Operating loss | (55,470) | (41,921) | (95,250) | (81,081) |
| Other income (expense), net: |
Item 1. Financial Statements.
FAQ
- What is Odyssey Therapeutics's total revenue?
- Odyssey Therapeutics (ODTX) reported total revenue of $0 in Q2 2026.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Odyssey Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude